Aprea Therapeutics, Inc. (APRE) financial statements (2022 and earlier)

Company profile

Business Address 535 BOYLSTON STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments53,07689,018130,089
Cash and cash equivalents53,07689,018130,089
Other undisclosed current assets3,5083,3992,956
Total current assets:56,58492,417133,045
Noncurrent Assets
Operating lease, right-of-use asset186321521
Property, plant and equipment243942
Other noncurrent assets29290
Total noncurrent assets:239389563
TOTAL ASSETS:56,82392,805133,608
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,6226,9173,827
Accounts payable1,7734,5042,177
Accrued liabilities430898688
Employee-related liabilities1,4181,515962
Debt  242
Other undisclosed current liabilities3,6958,4154,992
Total current liabilities:7,31615,3319,062
Noncurrent Liabilities
Long-term debt and lease obligation 79303
Operating lease, liability 79303
Other undisclosed noncurrent liabilities (79) 
Total noncurrent liabilities: 79303
Total liabilities:7,31615,4109,364
Stockholders' equity
Stockholders' equity attributable to parent49,50777,395124,244
Common stock222121
Additional paid in capital240,978231,418226,285
Accumulated other comprehensive loss(10,359)(10,037)(11,534)
Accumulated deficit(181,134)(144,007)(90,528)
Total stockholders' equity:49,50777,395124,244
TOTAL LIABILITIES AND EQUITY:56,82392,805133,608

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Operating expenses(37,446)(52,811)(29,544)
Operating loss:(37,446)(52,811)(29,544)
Nonoperating income (expense)636(1,558)1,484
Foreign currency transaction gain (loss), before tax317(890) 
Other nonoperating income (expense)319(668)1,484
Loss before gain (loss) on sale of properties:(36,810)(54,369)(28,060)
Other undisclosed net income (loss)(317)890 
Net loss available to common stockholders, diluted:(37,127)(53,479)(28,060)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(37,127)(53,479)(28,060)
Comprehensive loss:(37,127)(53,479)(28,060)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(322)1,497(2,772)
Comprehensive loss, net of tax, attributable to parent:(37,449)(51,982)(30,832)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: